This article has Open Peer Review reports available.
Atrial fibrillation in chronic dialysis patients in the United states: risk factors for hospitalization and mortality
© Abbott et al; licensee BioMed Central Ltd. 2003
Received: 23 October 2002
Accepted: 24 January 2003
Published: 24 January 2003
The incidence and risk factors for hospitalized atrial fibrillation have not been previously assessed in a national population of dialysis patients.
We analyzed the United States Renal Data System (USRDS) Dialysis Morbidity and Mortality Study (DMMS) Wave II in a historical cohort study of hospitalized atrial fibrillation. Data from 3374 patients who started dialysis in 1996 with valid follow-up times were available for analysis, censored at the time of renal transplantation and followed until November 2000. Cox Regression analysis was used to model factors associated with time to first hospitalization for atrial fibrillation (ICD9 code 427.31x) adjusted for comorbidities, demographic factors, baseline laboratory values, blood pressures, dialysis modality, and cardioprotective medications.
The incidence density of atrial fibrillation was 12.5/1000 person years. Factors associated with atrial fibrillation were older age (> = 71 years vs. <48 years), extremes (both high and low) of pre-dialysis systolic blood pressure, dialysis modality (hemodialysis vs. peritoneal dialysis), and digoxin use. Baseline use of coumadin was associated with reduced mortality in patients later hospitalized for atrial fibrillation.
Dialysis patients had a high incidence of atrial fibrillation. This risk was largely segregated among those with established risk factors for atrial fibrillation, and hemodialysis patients. Use of coumadin was associated with improved survival among patients later hospitalized for atrial fibrillation.
Atrial fibrillation is thought to be more common in chronic dialysis patients than in the general population, although population based comparisons are not available.  Atrial fibrillation is worthy of separate study from other dysrythmias due to unique aspects of its natural history and management.  Risk factors for atrial fibrillation may be more common in dialysis, and include age, cardiac enlargement and an abnormal calcium-phosphorous metabolism. [2–5] However, the incidence, risk factors and associated mortality for hospitalized atrial fibrillation have not been reported for a national population of chronic dialysis patients. Previous studies have also not assessed the effects of cardioprotective medications on atrial fibrillation in dialysis patients. The management of chronic dialysis patients with atrial fibrillation is controversial, since studies of atrial fibrillation have generally excluded patients with chronic renal failure. [6, 7] We therefore performed an historical cohort study of the United States Renal Data System (USRDS) Dialysis Morbidity and Mortality Study (DMMS) Wave 2, which includes information on blood pressure, lipid levels, medications, and other important clinical data. Our objectives were to determine the incidence, and risk factors for hospitalized atrial fibrillation (primary hospitalization discharge ICD9 code 427.31.x), occurring after the initiation of dialysis but prior to receipt of renal transplantation, as well as determine risk factors for mortality after hospitalized atrial fibrillation.
Factors assessed in ESRD patients, DMMS Wave 2, 1996 only
N (%) or mean ± SD
Univariate association with AFIB
Mean Age (Years)
58.9 ± 15.9
Quartiles of Age (vs. <48)
History of Coronary Heart Disease
History of Congestive Heart Failure
Chronic Obstructive Lung Disease
Previous coronary angiography
2nd quartile of pre-dialysis SBP (130–146 mm Hg) vs. 1st (<130 mm Hg)
CKD specific factors
Ever Transplanted (Yes/No)
Calcium Channel Blockers
Survival status was linked to the DMMS Wave 2 data from the 2000 USRDS Patients Standard Analysis File (SAF.PATIENTS) via unique patient identifiers assigned by the USRDS. The date and cause of death listed in a patient's SAF was obtained from a form submitted to the USRDS by the patient's nephrologist (form HCFA 2746). Patient survival status was complete through 6 November 2000. Hospitalization data was complete through 31 December 1999. Hospitalization data for atrial fibrillation (ICD9 codes 427.31x) were also linked to the DMMS Wave 2 data as above from SAF.HOSP, using only the first hospitalization for a given patient during the study period.
Time to hospitalization for atrial fibrillation was defined as the time from 90 days after the date of the first dialysis session until the first hospitalization for atrial fibrillation, censored for death, receipt of renal transplant, loss to followup or the end of the study period (which was considered 31 Dec 1999 since this was the most recent potential date of hospitalization available in the data files). Survival time was defined as the time from 90 days after the date of the first dialysis session until the date of death, censored for receipt of renal transplant, loss to followup or the end of the study period (which was considered 6 November 2000 since this was the most recent date of death specified in the data files).
Univariate analysis was performed with Chi-Square testing for categorical variables (Fisher exact test used for violations of Cochran's assumptions) and student's t-test for continuous variables (Mann Whitney test was used for variables without a Gaussian distribution). Variables with borderline significance (p value < 0.1 in univariate analysis) and those thought likely to have a clinical relationship with atrial fibrillation, such as cardioprotective medications and blood pressure, were entered into the multivariate models. In addition, variables thought to have a likely clinical relationship with atrial fibrillation were also entered into the multivariate model, in accordance with established epidemiological principles.  Stepwise (forward likelihood ratio method) Cox proportional hazards analysis was used to assess the association between baseline factors and hospitalized atrial fibrillation, independent of other factors. Log-log plots were inspected to verify the existence of proportional hazards. Estimated hazard ratios (HR) along with corresponding 95% confidence intervals (CI) and p values are reported for all regression covariates. Stepwise logistic regression was used to test the independent association of patient factors with preexisting coumadin and cardioselective beta-blocker use, using the same covariates as Cox Regression above. The association of atrial fibrillation with mortality as a time-dependent variable was tested by Cox non-proportional hazards regression analysis as previously described.  Hierarchically well-formed models were used in the assessment of interaction terms.  Collinearity diagnostics were evaluated both from the output of the statistical procedures and by manual generation of models including only one of several variables with close relationships (for example, congestive heart failure and left ventricular hypertrophy, which was assessed by chest X-ray, electrocardiogram, and echocardiography). Propensity scores [20, 21] have been used to adjust for confounding in baseline medication use. Since this method is primarily undertaken to assess uniformity of risk among strata, model fitting was also tested by fitting models to a 70% random sample of the study population, and then running the same model for the remaining 30% of the population to test for agreement.
A total of 4065 patients were included in the DMMS Wave 2 cohort. Of these, 3621 patients had valid dates for starting dialysis in 1996. From this cohort, 3374 had sufficient information to calculate follow-up times. During the time of the study period, 123 patients were hospitalized for a primary discharge diagnosis of atrial fibrillation, with an incidence density of 12.5/1000 person years.
Unadjusted rates of Atrial Fibrillation by high-risk groups
Patients in each risk group Hospitalized for atrial fibrillation
> = 71
< = 48
Pre-Dialysis SBP, mm Hg (Quartiles)
LVH by ECHO
Cox Regression Analysis of Factors Associated with Hospitalized Atrial Fibrillation
Age > = 71 (vs. <48)
Hemodialysis (vs. PD)
Digoxin use (1 = present, 0 = absent)
Pre-Dialysis SBP, mm Hg (vs. <130)
Survival after Hospitalization for Atrial fibrillation
Survival after hospitalization for atrial fibrillationA
Survival for entire cohortB
Cox Regression Analysis of Factors Associated with Mortality in Patients with Hospitalized Atrial Fibrillation
Coumadin use Quartiles of Predialysis SBP, mm Hg (vs. <130)
Quartiles of Predialysis SBP, mm Hg (vs. <130)
In agreement with some previous studies in the general population [1,4] and preliminary reports from the USRDS,  atrial fibrillation was associated with increased mortality among chronic dialysis patients. In the general population, cardiovascular events, and not thromboembolic events, are the most common cause of death after atrial fibrillation,  in agreement with the findings of the present analysis. However, it is also possible that thromboembolic events could have been underdiagnosed due to a low index of suspicion for thromboembolism in chronic dialysis patients, [24–26] because of the high number of deaths with an unknown cause, the low rate of autopsies in this population, or a combination of these factors. Vazquez et al  provide further evidence that causes of death may underestimate the incidence of embolic events in chronic dialysis patients with atrial fibrillation. They reported that 35% of chronic dialysis patients with atrial fibrillation suffered thromboembolic events at one year of followup.
Risk factors for atrial fibrillation in chronic dialysis patients were consistent with established risk factors [4, 5, 27], except for the association with hemodialysis (compared with those on peritoneal dialysis). In addition to age, left ventricular hypertrophy is also a well-established risk factor for atrial fibrillation in the general population. Many markers for cardiovascular comorbidity were associated with atrial fibrillation in univariate analysis (Table 1), but not in multivariate analysis (Table 3). While the efficacy of cardioversion in successful conversion of atrial dysrythmias may be helpful in some settings, it is less useful than the duration of the dysrythmia in patients with atrial fibrillation.  However, it has never been established whether the same guidelines apply to dialysis patients. The present study could not assess whether cardiac enlargement affected the success rate of cardioversion in dialysis patients hospitalized for atrial fibrillation.
Pre-dialysis systolic blood pressure exhibited a "U" shaped relationship with the risk of atrial fibrillation, which is similar to the "U" shaped relationship of blood pressure with mortality and other cardiovascular events in chronic dialysis patients. Recent reports have indicated that pulse pressure is a more predictive indicator of cardiovascular events in dialysis patients than either systolic or diastolic blood pressure separately.  However, pulse pressure was not independently associated with atrial fibrillation in our analysis.
Hemodialysis was associated with a significantly higher risk of atrial fibrillation than peritoneal dialysis in the present study. It is possible this association represents bias, since hemodialysis patients present for medical care much more frequently than peritoneal dialysis patients, and asymptomatic atrial fibrillation is more readily detected. However, there are legitimate reasons why atrial fibrillation might occur more frequently on hemodialysis than on peritoneal dialysis. First, Foley et al demonstrated that progressive cardiac enlargement was more frequent in hemodialysis patients than peritoneal dialysis patients,  although these findings were not replicated in a Japanese study.  Other investigators have confirmed that LVH progresses despite adequate blood pressure control in hemodialysis patients.  Also, hospitalized congestive heart failure is more common in hemodialysis than peritoneal dialysis patients, especially for those on the renal transplant waiting list.  The typical regimen for hemodialysis is likely far less physiologic than peritoneal dialysis. Residual renal function may also be preserved longer in patients on peritoneal dialysis, although this is controversial. [33, 34] Some or all of these factors may therefore mediate the higher risk of atrial fibrillation associated with hemodialysis.
The effectiveness of coumadin for atrial fibrillation in chronic dialysis patients has not been assessed previously. In fact, previous reports considered chronic renal failure a contraindication to the use of anticoagulation in atrial fibrillation.  Wiesholzer et al concluded that non-rheumatic atrial fibrillation was not an independent risk factor for stroke in dialysis patients.  Therefore, Figure 2 suggests several possibilities. First, although the clinical indications for coumadin use in this cohort were unknown, coumadin is often given for a limited period of time , after which it is often discontinued, in the absence of known predisposing factors. Therefore, patients who were using coumadin at the time of the study assessment and later discontinued it might not have been taking coumadin at the time they were hospitalized for atrial fibrillation, negating a possible beneficial association of coumadin with mortality after hospitalization for atrial fibrillation. Another possibility is that many patients not taking coumadin at baseline may have later been treated with coumadin after hospitalization for atrial fibrillation. Given the growing evidence that dialysis patients in the modern era may actually be hypercoagulable, primarily due to defects of the fibrinolytic system, [25, 37, 38] clinical trials of the use of anticoagulation in atrial fibrillation and thromboembolic disorders are warranted. Of note, baseline coumadin use, in contrast to digoxin use, was not associated with hospitalization for atrial fibrillation and therefore presumably was not a marker for patients with pre-existing atrial fibrillation.
The decision to use coumadin in patients with atrial fibrillation in whom NSR cannot be established is based on an assessment of both their risk of serious bleeding and their risk of stroke. Coumadin therapy has been associated with improved survival in patients with reduced LV systolic dysfunction in the absence of dysrythmias as well, primarily through reduction in cardiovascular events rather than reduction of thromboembolic events.  This may be one explanation for the association of coumadin use with reduced mortality in chronic dialysis patients hospitalized for atrial fibrillation in the present study.
The present study was observational and not randomized, and therefore associations should not be construed as causative. The study is a random sample of all hemodialysis patients, not the total population, although the peritoneal dialysis population was almost fully captured. We did not have access to information on treatment or conversion to NSR in patients who were hospitalized for atrial fibrillation, nor did we have information on the type of atrial fibrillation for which patients presented and how it was classified within ACC/AHA/ESC guidelines.  We did not have access to information on which patients had self-limited episodes of atrial fibrillation vs. those who had persistent atrial fibrillation, nor the duration or presence of atrial fibrillation prior to hospitalization or the study start. We did not have information on left atrial size other than the presence of LVH on echocardiography. We also did not have information on thyroid functions (other than baseline use of thyroxine), alcohol use, or pre-existing atrial dysrythmias. Information bias could have arisen due to mistakes in coding or spelling, especially for medications. We were unable to follow changes in variables over time. Therefore, we could not follow changes in blood pressure, laboratory values, dialysis adequacy, or medications. We could not assess other factors that have shown to be associated with atrial fibrillation, such as hypokalemia or calcified aortic/mitral valves,  although there are many similarities between the risk factors for valvular heart disease and atrial fibrillation in chronic dialysis patients.  Our use of atrial fibrillation as an outcome variable required survival to reach hospitalization, and thus sudden death was not considered as an outcome. However, causes of death, especially if not verified by autopsy, are also of questionable validity in comparison to the rates of total mortality. 
In summary, the present observational, non-randomized study confirms the high incidence and mortality of atrial fibrillation in chronic dialysis patients. Traditional risk factors for atrial fibrillation such, as older age, were confirmed. Hemodialysis, possibly due to a greater frequency of progressive cardiac enlargement or more frequent observation, was also identified as a risk factor for atrial fibrillation. Of the greatest potential importance, the use of coumadin at the start of the study was associated with lower mortality in patients later hospitalized for atrial fibrillation. These findings should be confirmed in clinical trials.
- Zebe H: Atrial fibrillation in dialysis patients. Nephrol Dial Transplant. 2000, 15: 765-8. 10.1093/ndt/15.6.765.View ArticlePubMedGoogle Scholar
- Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998, 54: 1720-5. 10.1046/j.1523-1755.1998.00154.x.View ArticlePubMedGoogle Scholar
- Ansari N, Manis T, Feinfeld DA: Symptomatic atrial arrhythmias in hemodialysis patients. Ren Fail. 2001, 23: 71-6. 10.1081/JDI-100001285.View ArticlePubMedGoogle Scholar
- Fabbian F, Catalano C, Lambertini D, Tarroni G, Bordin V, Squerzanti R, Gilli P, Di Landro D, Cavagna R: Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol. 2000, 54: 234-9.PubMedGoogle Scholar
- Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, Gil JM, Borrego MJ, Perez V: Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000, 140: 886-90. 10.1067/mhj.2000.111111.View ArticlePubMedGoogle Scholar
- SPAF Investigators: The Stroke Prevention in Atrial Fibrillation Study Group Investigators: final results. Circulation. 1991, 84: 527-39.View ArticleGoogle Scholar
- Stroke Prevention in Atrial Fibrillation investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996, 348: 633-8. 10.1016/S0140-6736(96)03487-3.View ArticleGoogle Scholar
- Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 2001, 12: 1516-23.PubMedGoogle Scholar
- Stack AG, Bloembergen WE: A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis. 2001, 38: 992-1000.View ArticlePubMedGoogle Scholar
- Stehman-Breen CO, Gillen D, Gipson D: Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney Int. 1999, 56: 2243-7. 10.1046/j.1523-1755.1999.00793.x.View ArticlePubMedGoogle Scholar
- Stehman-Breen CO, Sherrard DJ, Gillen D, Caps M: Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int. 2000, 57: 639-45. 10.1046/j.1523-1755.2000.00885.x.View ArticlePubMedGoogle Scholar
- [No authors listed]: Medication use among dialysis patients in the DMMS. United States Renal Data System. Dialysis Morbidity and Mortality Study. Am J Kidney Dis. 1998, 32 (2 Suppl 1): S60-8.Google Scholar
- Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball A, Stehman-Breen C: Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis. 2002, 40: 307-14. 10.1053/ajkd.2002.34509.View ArticlePubMedGoogle Scholar
- Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002, 61: 297-304. 10.1046/j.1523-1755.2002.00109.x.View ArticlePubMedGoogle Scholar
- Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 2002, 61: 2157-64. 10.1046/j.1523-1755.2002.00355.x.View ArticlePubMedGoogle Scholar
- Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC: Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002, 62: 1799-1805. 10.1046/j.1523-1755.2002.00638.x.View ArticlePubMedGoogle Scholar
- Szklo M, Nieto FJ: Epidemiology: Beyond the Basics. Chapter 7, "Stratification and Adjustment: Multivariate Analysis in Epidemiology," page 257. © Aspen Publishers, Gaithersburg, MD. 2000Google Scholar
- Hypolite IO, Bucci J, Hshieh P, Cruess D, Agodoa LY, Yuan CM, Taylor AJ, Abbott KC: Acute coronary syndromes after renal transplantation in patients with end-stage renal disease resulting from diabetes. Am J Transplant. 2002, 2: 274-81. 10.1034/j.1600-6143.2002.20313.x.View ArticlePubMedGoogle Scholar
- David Kleinbaum: Survival Analysis : A Self-Learning Text (Statistics in the Health Sciences) Springer Verlag; New York, New York. May 1996Google Scholar
- Mehta RL, McDonald B, Gabbai F, Pahl M, Farkas A, Pascual MT, Zhuang S, Kaplan RM, Chertow GM: Nephrology consultation in acute renal failure: does timing matter?. Am J Med. 2002, 113: 456-61. 10.1016/S0002-9343(02)01230-5.View ArticlePubMedGoogle Scholar
- Stata corporation. [http://www.iue.it/Personal/Ichino/psj7.pdf]
- Wattigney WA, Mensah GA, Croft JB: Increased atrial fibrillation mortality: United States, 1980–1998. Am J Epidemiol. 2002, 155: 819-26. 10.1093/aje/155.9.819.View ArticlePubMedGoogle Scholar
- Casserly LF, Reddy SM, Dember LM: Venous thromboembolism in end-stage renal disease. Am J Kidney Dis. 2000, 36: 405-11.View ArticlePubMedGoogle Scholar
- Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC: Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis. 2002, 39: 1011-7. 10.1053/ajkd.2002.32774.View ArticlePubMedGoogle Scholar
- Tveit DP, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC: Risk factors for pulmonary embolism in chronic dialysis patients. J Nephrol. 2002, 15: 241-7.PubMedGoogle Scholar
- Fumagalli S, Boncinelli L, Bondi E, Caleri V, Gatto S, Di Bari M, Baldereschi G, Valoti P, Masotti G, Marchionni N: Does advanced age affect the immediate and long-term results of direct-current external cardioversion of atrial fibrillation?. J Am Geriatr Soc. 2002, 50: 1192-7. 10.1046/j.1532-5415.2002.50304.x.View ArticlePubMedGoogle Scholar
- Asinger RW: Role of transthoracic echocardiography in atrial fibrillation. Echocardiography. 2000, 17: 357-64.View ArticlePubMedGoogle Scholar
- Tozawa M, Iseki K, Iseki C, Takishita S: Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. 2002, 61: 717-26. 10.1046/j.1523-1755.2002.00173.x.View ArticlePubMedGoogle Scholar
- Takeda K, Nakamoto M, Baba M, Tanaka T, Yasunaga C, Nishihara G, Matsuo K, Urabe M: Echocardiographic evaluation in long-term continuous ambulatory peritoneal dialysis compared with the hemodialysis patients. Clin Nephrol. 1998, 49: 308-12.PubMedGoogle Scholar
- Covic A, Goldsmith DJ, Georgescu G, Venning MC, Ackrill P: Echocardiographic findings in long-term, long-hour hemodialysis patients. Clin Nephrol. 1996, 45: 104-10.PubMedGoogle Scholar
- Abbott KC, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Taylor AJ, Yuan CM: The impact of renal transplantation on the incidence of congestive heart failure in patients with end-stage renal disease due to diabetes. J Nephrol. 2001, 14: 369-76.PubMedGoogle Scholar
- Buoncristiani U, Fagugli R, Ciao G, Ciucci A, Carobi C, Quintaliani G, Pasini P: Left ventricular hypertrophy in daily dialysis. Miner Electrolyte Metab. 1999, 25: 90-4. 10.1159/000057427.View ArticlePubMedGoogle Scholar
- Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT: Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002, 62: 1046-1053. 10.1046/j.1523-1755.2002.00505.x.View ArticlePubMedGoogle Scholar
- Lip GY, Tean KN, Dunn FG: Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994, 71: 92-5.View ArticlePubMedPubMed CentralGoogle Scholar
- Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P: Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001, 21: 35-9. 10.1159/000046216.View ArticlePubMedGoogle Scholar
- Oda H, Ohno M, Ohashi H: Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial. 2000, 16: 152-5.PubMedGoogle Scholar
- Lottermoser K, Petras S, Poge U, Fimmers R, Hertfelder HJ, Schiermeyer B, Vetter H, Dusing R: The fibrinolytic system in chronic renal failure. Eur J Med Res. 2001, 6: 372-6.PubMedGoogle Scholar
- Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998, 31: 749-53. 10.1016/S0735-1097(98)00006-0.View ArticlePubMedGoogle Scholar
- Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A: ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001, 104 (17): 2118-50.PubMedGoogle Scholar
- Korzets A, Ori Y, Herman M: Serum potassium levels and atrial fibrillation in haemodialysis patients. Nephrol Dial Transplant. 2001, 16: 1090-10.1093/ndt/16.5.1090. LetterView ArticlePubMedGoogle Scholar
- Abbott KC, Agodoa LY: Hospitalizations for valvular heart disease in chronic dialysis patients in the United States. Nephron. 2002, 92: 43-50. 10.1159/000064476.View ArticlePubMedGoogle Scholar
- Schall LC, Buchanich JM, Marsh GM, Bittner GM: Utilizing multiple vital status tracing services optimizes mortality follow-up in large cohort studies. Ann Epidemiol. 2001, 11: 292-296. 10.1016/S1047-2797(00)00217-9.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/4/1/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.